In the same way, CXCL10 expression in U87i and U87w lysates was increased in BBB model with PBMCs from control patients (by 70.41-fold and by 85.03-fold respectively) and from mild AD patients (by 79.69-fold and by 93.93-fold respectively) versus U87i and U87w lysates in BBB models without PBMCs (Table 3). The gene discussed is CXCL10; the disease is Alzheimer disease.